NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

Core Viewpoint - NextCure, Inc. is advancing its clinical-stage biopharmaceutical efforts with the presentation of a Phase 1 study poster for LNCB74, a B7-H4 targeted antibody-drug conjugate, at the ASCO Annual Meeting, highlighting its potential in treating various advanced solid tumors [1][3]. Company Overview - NextCure, Inc. is focused on developing innovative cancer therapies for patients who do not respond to existing treatments, utilizing differentiated mechanisms such as antibody-drug conjugates, antibodies, and proteins [4]. Study Details - The Phase 1 study is evaluating LNCB74 as a monotherapy for advanced solid tumors, including platinum-resistant ovarian cancer, treatment-refractory breast cancer, endometrial cancer, biliary tract cancer, and squamous non-small cell lung cancer, with ongoing dose escalation [2][7]. - The study includes phases for dose escalation, dose expansion, and optimization, currently enrolling participants in the dose escalation phase [2][7]. Target and Efficacy - B7-H4 is identified as an attractive target for ADC therapy due to its high expression in multiple tumor types and limited expression in normal tissues, with LNCB74 showing a superior safety profile and potent anti-tumor activity in preclinical studies [3].